ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

Story continues below

September15, 2017, was Bryan Shaw’s last day of employment with Ardelyx, Inc. (the “Company”). Mr. Shaw served the Company as Vice President, Corporate Controller and Chief Accounting Officer from December 1, 2016 through September15, 2017. The Company expects to provide Mr.Shaw with the severance benefits set forth in his previously filed Change of Control Severance Agreement, conditioned upon the receipt of a general release of claims against the Company.

In addition, on September15, 2017, the Company appointed its current Chief Financial Officer, Mark Kaufmann, to the role of Principal Accounting Officer, effective as of September15, 2017. Mr.Kaufmann has served as the Company’s Chief Financial Officer since May 2014, and formerly served as our Chief Business Officer from August 2011 until May 2014. His compensation shall not change as a result of this appointment. Mr.Kaufmann has not been involved in any transactions that would require disclosure under Item 404(a) of Regulation S-K.


About ARDELYX, INC. (NASDAQ:ARDX)

Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.

An ad to help with our costs